Selecta Biosciences (NASDAQ:SELB) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Selecta Biosciences (NASDAQ:SELBGet Rating) announced its earnings results on Thursday. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.09, Fidelity Earnings reports. Selecta Biosciences had a net margin of 24.85% and a return on equity of 21.22%. During the same quarter in the prior year, the business earned ($0.04) earnings per share.

Selecta Biosciences Trading Up 25.5 %

Shares of SELB stock opened at $2.36 on Friday. The business’s fifty day moving average price is $1.39 and its 200 day moving average price is $1.44. Selecta Biosciences has a 1-year low of $0.65 and a 1-year high of $4.70. The firm has a market capitalization of $358.27 million, a PE ratio of 236.00 and a beta of 1.04. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.31 and a quick ratio of 3.31.

Insider Buying and Selling

In other Selecta Biosciences news, Director Carrie Smith Cox acquired 130,000 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average price of $1.15 per share, with a total value of $149,500.00. Following the completion of the acquisition, the director now directly owns 212,881 shares of the company’s stock, valued at approximately $244,813.15. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Carrie Smith Cox bought 130,000 shares of the stock in a transaction on Monday, June 13th. The shares were bought at an average price of $1.15 per share, with a total value of $149,500.00. Following the completion of the acquisition, the director now owns 212,881 shares of the company’s stock, valued at $244,813.15. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Timothy C. Barabe bought 50,000 shares of the stock in a transaction on Monday, May 9th. The stock was purchased at an average cost of $0.77 per share, for a total transaction of $38,500.00. Following the acquisition, the director now directly owns 250,013 shares of the company’s stock, valued at approximately $192,510.01. The disclosure for this purchase can be found here. 30.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Selecta Biosciences

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Selecta Biosciences by 10.1% in the first quarter. Vanguard Group Inc. now owns 5,690,224 shares of the company’s stock valued at $6,999,000 after acquiring an additional 521,993 shares in the last quarter. XTX Topco Ltd lifted its position in shares of Selecta Biosciences by 261.9% in the first quarter. XTX Topco Ltd now owns 121,614 shares of the company’s stock valued at $150,000 after acquiring an additional 88,014 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Selecta Biosciences by 213.0% in the first quarter. Renaissance Technologies LLC now owns 1,490,400 shares of the company’s stock valued at $1,833,000 after acquiring an additional 1,014,200 shares in the last quarter. State Street Corp lifted its position in shares of Selecta Biosciences by 4.7% in the first quarter. State Street Corp now owns 1,790,985 shares of the company’s stock valued at $2,203,000 after acquiring an additional 80,662 shares in the last quarter. Finally, Eqis Capital Management Inc. purchased a new stake in shares of Selecta Biosciences in the first quarter valued at $30,000. Institutional investors and hedge funds own 72.62% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. SVB Leerink assumed coverage on shares of Selecta Biosciences in a research note on Monday, June 6th. They set an “outperform” rating and a $7.00 target price for the company. Needham & Company LLC decreased their target price on shares of Selecta Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, June 14th. TheStreet upgraded shares of Selecta Biosciences from a “d” rating to a “c-” rating in a research note on Wednesday, May 25th. HC Wainwright dropped their target price on Selecta Biosciences from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 21st. Finally, StockNews.com downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 14th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.33.

Selecta Biosciences Company Profile

(Get Rating)

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.

Read More

Earnings History for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.